We observed that in the concentration of NLRP3 and IL-1β there was no statistically significant difference in both groups of patients, which would confirm what was previously reported about the activity of the inflammasome present in SSc [29]; this was explored by Diude et al., who established an association between the NLRP1 rs8182352 variant and the development of fibrosis in patients with SSc [30]. Here, NLRP3 is linked to systemic sclerosis.